US Stem Cell Inc (USRM)

[TheHungryHippo]

10 Regenerative Medicine Stocks & USRM

I am not the best at financials, and if anyone wants to correct me feel free, but just out of curiosity I'd like to examine other Stem Cell companies and compare them to USRM. I took all these numbers from the most recent 10q's of each company, and most up to date info I could find. This is open for discussion, and imo a very complex situation. Let's just take a glance and ponder, but be mindful that NONE of these companies have FDA approval for their Stem Cell therapies/products... They are ALL going through Clinical Trials. Each company displays a tremendous risk/reward and unique situation. Which companies will be among some of the first to receive FDA approval for Stem Cell therapies? Could USRM become one of the first? With the recent passing of The Cures Act, will USRM be a major benefactor?

Some of the share structures from the other stem cell companies are not that different from USRM as to where they are trading in dollars and USRM is trading sub-penny with such a small market value. We can begin to make our case as to why USRM is undervalued with the advancement of the most recent clinical trials for degenerative disc disease, and the wealth of developments throughout the years since the inception of US Stem Cell Inc.

Once again I refer to this part of the most recent filing as a potential clue of what could be possible here trading this stock:


1. US. Stem Cell Inc. (USRM)
http://us-stemcell.com/en/home-2/

Summary:
U.S. Stem Cell’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

Market Value1 $250,209 a/o Jan 27, 2017
Authorized Shares: 2,000,000,000 a/o Aug 02, 2016
Outstanding Shares: 59,573,684 a/o Nov 09, 2016 (Most Estimate 80-90million now)
Current Price: $.0042
Current liabilities: $6.96M in Q3 2016
Assets: $413,316
Revenue: $729K in Q3 2016
Net loss improved: $219K in Q3 2016
Cash used in operating activities: $62k in Q3 2016
Cash at end of period: $245,991



Sources:
http://us-stemcell.com/ceo-blog-november2016/
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975

2. Athersys, Inc. (ATHX) Nasdaq
http://www.athersys.com

Summary:
We currently have six clinical stage programs – including a pending Phase 3 study in ischemic stroke, an ongoing Phase 2 clinical study for the treatment of damage from acute myocardial infarction, an ongoing exploratory clinical study in Acute Respiratory Distress Syndrome, and several others. We also have a portfolio of preclinical programs that we are advancing toward clinical stage development.

Current Price: $1.12
Net Loss: (6,004)
Assets: $23,319.00
Current Liabilities: $23,319.00
Revenue: $150.00 (yes 150 dollars)
Cash used in operating activities: (4,647) (yes that is negative $4,647.00)
Cash at end of period: $8,309

Source:
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11678481



3. Cytori Therapeutics, Inc. (CYTX )Nasdaq
http://www.cytori.com
Upcoming merger: CYTORI TO ACQUIRE AZAYA THERAPEUTICS

Summary:
Cytori Therapeutics, Inc. is dedicated to enhancing lives through novel cell therapies. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we deliver meaningful results that create exceptional value for our patients, partners, employees, shareholders, and society.

Authorized: 75 million
Outstanding Shares 20,500,553 a/o Oct 31, 2016
Current Price: $1.59
Assets: $36,842,000
Current Liabilities: $23,172,000
Revenue: $731,000
Cash used in operating activities: (15,372,000)
Cash at end of period: $14,924,000

https://www.otcmarkets.com/stock/CYTX/filings




4. Cesca Therapeutics Inc. (KOOL) Nasdaq
http://cescatherapeutics.com/blood-marrow-processing/

Summary: Cesca has developed a complete suite of BioProcess technologies to cater to the needs of the Bio-banking, and regenerative medicine market. Our technology is designed specifically for the following groups:
Clinical Development Companies (integrating GMP compliant technologies for manufacturing and storage process control)
Commercialization stage companies upgrading their process to include GMP compliant...
Biobanking Facilities

Authorized Share Count: 350,000,000
Outstanding Shares: 9,790,500 a/o Sep 16, 2016
Net Loss: (22,445)
Current Price: $2.96
Assets: $49,185
Current Liabilities: $12,858
Revenue: $3,767
Cash used in operating activities: (2,009)
Cash at end of period: $5,835

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11678481


5. Capricor Inc. (CAPR) Nasdaq

Summary:
"This is an adult stem-cell company; they are going after big-ticket items like the cardiovascular space, and the data to date has shown some promise," Benjamin said. "And J&J (Johnson & Johnson (JNJ)) actually has option to potentially move forward with the company and the therapeutic if they like the next set of data that comes out, probably sometime next year."
https://www.thestreet.com/story/13238523/1/four-stem-cell-stocks-with-promise.html

Market Value $48,361,783 a/o Jan 27, 2017
Authorized Shares 50,000,000 a/o Nov 12, 2014
Outstanding Shares 21,399,019 a/o Nov 11, 2016
Current Price: $2.26
Assets: $24,471,820
Current Liabilities: $6,670,268
Total Income: $746,781
Net Loss: (5,333,413)
Cash at end of period: $18,020,875

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11687134




6. Pluristem (PSTI) Nasdaq Israeli based
http://www.pluristem.com

Summary:
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation.

Market Value $89,122,095 a/o Jan 27, 2017
Authorized Shares Not Available
Outstanding Shares 81,020,086 a/o Nov 02, 2016
Current Price: $1.10
Operating loss: (6,562)
Net loss: $(6,324)
Revenue: 0
Net cash used by operating activities: $(3,923)
Assets: $40,209
Current Liabilities: $40,209




7. International Stem Cell Corporation (ISCO)
http://internationalstemcell.com/company/

Summary:
International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.


Market Value $4,079,820 a/o Jan 27, 2017
Authorized Shares 120,000,000 a/o Sep 30, 2016
Outstanding Shares 3,642,696 a/o Nov 12, 2016
Current Price: $1.12
Cash on hand: $733
Operating loss: (6,562)
Net loss: $414
Revenue: (1,262)
Loss from operating activities (1,262)
Assets: $7,540
Current Liabilities: $7,540

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11686960



8. Stemline Therapeutics, Inc. (STML)
http://www.stemline.com
Summary:
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Current Price: $10.20
Grant revenue $299,401
Outstanding Share Count: 19,151,652
Total liabilities 9,275,544
Net loss$ (9,923,222)

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11675126



9. Asterias Bio therapeutics Inc., (AST) AMEX
http://asteriasbiotherapeutics.com

Summary:
Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 14 & 30 days after injury. Researchers will also assess the impact on patient hand & arm function.

Current Price : $4.35
Market Value $201,937,666 a/o Jan 27, 2017
Authorized Shares Not Available
Outstanding Shares 46,422,452 a/o Nov 10, 2016
TOTAL ASSETS $70,303
TOTAL LIABILITIES $27,577
Total gross profit: 2,017



10. BioTime Inc. (BTX) (embriotic stem cells controversial studies with fetus stem cells)

Summary:
Macular degeneration affects approximately 11 million people in the U.S. It is the leading cause of blindness in people over the age of 60. Approximately 90 percent of these patients suffer from the dry form, for which there are no FDA-approved therapies.

Current Price: $3.18

Share Structure
Market Value1 $328,787,349 a/o Jan 27, 2017
Authorized Shares Not Available
Outstanding Shares 103,392,248 a/o Aug 05, 2016
http://www.businesswire.com/news/home/20170119005455/en/Additional-Data-BioTime’s-OpRegen®-Clinical-Trial-Dry-AMD




11. Oncomed (OMED) (Cancer research)
http://www.oncomed.com

Summary:
OncoMed Pharmaceuticals is a clinical-stage biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.

Outstanding Shares: 33,758,423
Current Price: $8.02
Total assets $218,188
Total Liabilities: 221,369
Revenue: 5,279